PubMed Health⌕ Search

Biomedical subjects

Cindy M Meston

Publications and source records attributed to Cindy M Meston.

4 recordsLinked to original sources

The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder.

This study examined the effects of the nitric oxide-precursor L-arginine combined with the alpha 2-blocker yohimbine on subjective and physiological sexual arousal in postmenopausal women with Female Sexual Arousal Disorder. Twenty-four women participated in three treatment sessions in which self-report and physiological (vaginal photoplethysmograph) sexual responses to erotic stimuli were measured following treatment with either L-arginine glutamate (6 g) plus yohimbine HCl (6 mg), yohimbine alone (6 mg), or placebo, using a randomized, double-blind, three-way cross-over design. Sexual responses were measured at approximately 30, 60, and 90 min postdrug administration. The combined oral administration of L-arginine glutamate and yohimbine substantially increased vaginal pulse amplitude responses to the erotic film at 60 min postdrug administration compared with placebo. Subjective reports of sexual arousal were significantly increased with exposure to the erotic stimuli but did not differ significantly between treatment groups.

Adrenergic alpha-Antagonists↗

Validated instruments for assessing female sexual function.

In this article, we review five instruments for assessing female sexual dysfunction (FSD): the Brief Index of Sexual Functioning for Women (BISF-W; Taylor, Rosen, & Leiblum, 1994), the Changes in Sexual Functioning Questionnaire (CSFQ; Clayton, McGarvy, & Clavet, 1997), the Derogatis Interview for Sexual Functioning (DISF/DISF-SR; Derogatis, 1997), the Female Sexual Function Index (FSFI; Rosen et al., 2000), and the Golombok Rust Inventory of Sexual Satisfaction (GRISS; Rust & Golombok, 1986). The purpose of this article is to highlight the psychometric properties of these questionnaires in an effort to assist researchers in selecting effective measurement tools for FSD.

Adult↗

Acute dehydroepiandrosterone effects on sexual arousal in premenopausal women.

The present investigation was designed to provide the first empirical examination of the effects of acute dehydroepiandrosterone (DHEA) administration on subjective and physiological sexual arousal in women. The primary purpose was to assess whether DHEA influences vaginal blood flow response in sexually functional women. Subjective (self-report) and physiological (vaginal photoplethysmograph) sexual responses to erotic stimuli were measured following DHEA (300 mg) and placebo administration in 12 sexually functional, premenopausal women, using a single-blind protocol. Acute DHEA significantly increased blood levels of dehydroepiandrosterone sulfate (DHEA-S) 30 min following drug administration but had no significant effect on either vaginal pulse amplitude responses or subjective responses to the erotic films. Acute DHEA does not appear to substantially influence sexual responding among sexually functional, premenopausal women.

Adjuvants, Immunologic↗

Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder.

The Female Sexual Functioning Index (FSFI; Rosen et al., 2000) is a self-report measure of sexual functioning that has been validated on a clinically diagnosed sample of women with female sexual arousal disorder. The present investigation extended the validation of the FSFI to include women with a primary clinical diagnosis of female orgasmic disorder (FOD; n = 71) or hypoactive sexual desire disorder (HSDD; n = 44). Internal consistency and divergent validity of the FSFI were within the acceptable range for these populations of women. Significant differences between women with FOD and controls and between women with HSDD and controls were noted for each of the FSFI domain and total scores.

Adult↗